Company Monitoring Page for Roche

latest headlines for company on cafepharma

FDA Advisory Committee to Review Checkpoint Inhibitors Greenlit Under Accelerated Approval
BioSpace
Sun, 04/25/21 - 01:56 pm
Tags:
FDA, oncology, cancer, accelerated approvals, Bristol Myers Squibb, Opdivo, Roche, Tecentriq, Merck, Keytruda
Roche's virtual gala raises multiple sclerosis awareness with celebrities—and personal connections
Fierce Pharma
Sun, 04/25/21 - 01:46 pm
Tags:
Roche, Genentech, pharma marketing, multiple sclerosis
The retreat of corporate venture funding?
EP Vantage
Fri, 04/23/21 - 11:02 am
Tags:
funding, venture funding, venture capital, AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, JNJ, Merck, Merck KGaA, Pfizer, Roche, Sanofi, Takeda
A look ahead at the FDA meeting that could decide the future of 6 cancer drug approvals
BioPharma Dive
Thu, 04/22/21 - 11:51 pm
Tags:
FDA, cancer immunotherapy, Merck, Roche, Bristol Myers Squibb, AstraZeneca
Roche sees a slight dip in Q1 as biosim­i­lars keep bit­ing in­to block­buster on­col­o­gy tri­o's sales
Endpoints
Wed, 04/21/21 - 10:40 am
Tags:
Roche, earnings, biosimilars
Roche culls 2 COVID-19 drug hopefuls amid Q1 clear-out
Fierce Biotech
Wed, 04/21/21 - 10:39 am
Tags:
Roche, antibodies, COVID-19
Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients
Endpoints
Fri, 04/16/21 - 09:57 am
Tags:
Roche, Ocrevus, MS, multiple sclerosis, clinical trials
6 medtechs to watch when earnings kick off next week
Medtech Dive
Fri, 04/16/21 - 09:49 am
Tags:
earnings, devices, Abbott Labs, Edwards Lifesciences, Intuitive Surgical, JNJ, Roche, Quest Diagnostics
Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med Actemra
Fierce Pharma
Thu, 04/15/21 - 11:21 am
Tags:
Novartis, COVID-19, Pfizer, BioNTech, CureVac, Roche, API, Actemra
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche
Pharmaforum
Thu, 04/15/21 - 10:02 am
Tags:
Roche, Genentech, Evrysdi, SMA
Senti Biosciences in $645M Spark pact to drive gene circuits into the fast lane
Fierce Biotech
Wed, 04/14/21 - 09:34 am
Tags:
Spark Therapeutics, Senti Biosciences, Roche, gene circuits, gene therapy
5 takeaways from AACR, one of the year's top meetings on cancer drugs
BioPharma Dive
Mon, 04/12/21 - 11:34 pm
Tags:
AACR, CAR-T, Merck, Roche, Sanofi, Synthorx, Eli Lilly, Bristol Myers Squibb
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
Fierce Pharma
Mon, 04/12/21 - 10:58 pm
Tags:
reputation, pharma industry, Sanofi, Novo Nordisk, Roche, Eli Lilly, Bristol Myers Squibb
Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers
Fierce Pharma
Thu, 04/1/21 - 11:37 pm
Tags:
Roche, Genentech, diversity
Go or no go? The FDA plays hardball
EP Vantage
Tue, 03/30/21 - 11:47 am
Tags:
FDA, Pfizer, Roche, Merck, Bristol Myers Squibb, accelerated approvals
Why Roche's $1.8 Billion Acquisition of GenMark Is a Smart Move
Motley Fool
Wed, 03/24/21 - 10:01 am
Tags:
Roche, GenMark, M&A
Regeneron and Roche's antibody cocktail shown helping in COVID-19 cases
Reuters
Tue, 03/23/21 - 10:42 am
Tags:
Regeneron, Roche, clincial trials, COVID-19
Roche cuts bait on late-stage study of Huntington's med tominersen, an Ionis import with prior safety flags
Endpoints
Mon, 03/22/21 - 09:56 pm
Tags:
Roche, Huntington's disease, tominersen
Roche's Tecentriq is the first I-O drug to claim a post-surgery win in lung cancer. But will doctors use it?
Fierce Pharma
Mon, 03/22/21 - 10:48 am
Tags:
Roche, Tecentriq, non-small cell lung cancer
Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll
Fierce Pharma
Thu, 03/18/21 - 11:01 am
Tags:
Horizon Therapeutics, Roche, Genentech, AbbVie, Neurocrine, employee satisfaction

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.